AUTHOR=George Siju C. , Samuel E. James Jebaseelan 

TITLE=Developments in 177Lu-based radiopharmaceutical therapy and dosimetry

JOURNAL=Frontiers in Chemistry

VOLUME=Volume 11 - 2023

YEAR=2023

URL=https://www.frontiersin.org/journals/chemistry/articles/10.3389/fchem.2023.1218670

DOI=10.3389/fchem.2023.1218670

ISSN=2296-2646

ABSTRACT=Lu is a radioisotope that has become increasingly popular as a therapeutic agent for treating various conditions, including neuroendocrine tumors and prostate cancer. 177 Lu-tagged radioligands are molecules precisely designed to target and bind to specific receptors or proteins. This review paper will present an overview of the available Lu-labelled radioligands currently used to treat patients. Based on recurring, active, and completed clinical trials and other available literature, we evaluate current status, interests, and developments in assessing patient-specific dosimetry, which will define the future of this particular treatment modality. In addition, we will discuss the challenges and opportunities of the existing dosimetry standards to measure and calculate the radiation dose delivered to patients, which is essential for ensuring treatments' safety and efficacy. Finally, this article intends to provide an overview of the current state of 177 Lu-tagged radioligand therapy and highlight the areas where further research can improve patient treatment outcomes.